<DOC>
	<DOC>NCT01777425</DOC>
	<brief_summary>State-of-the-art documents like ARIA and european position paper on rhinosinusitis (EPOS) provide clinicians with evidence-based treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS) respectively (1)(2) . The currently available medications can alleviate symptoms associated with AR and RS, and most patients with RS benefit from endoscopic sinus surgery (ESS). In real life, a significant percentage of patients with AR and CRS continue to experience bothersome symptoms despite adequate treatment. This group with so-called severe chronic upper airway disease (SCUAD) represents a therapeutic challenge (3).</brief_summary>
	<brief_title>Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)</brief_title>
	<detailed_description />
	<criteria>1. Patients that have undergone bilateral ESS for inflammatory sinonasal disease, without additional sinonasal surgery after the ESS. 2. Age &gt; 18 and &lt; 75 years. 3. Written informed consent 4. Dutch, French or English speaking patients 1. Unilateral ESS 2. Benign and malignant tumor disease 3. Patient with a psychiatric, addictive, or any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study or provide reliable information on the questionnaire 4. Lack of knowledge of Dutch, French or English</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>